Blincyto (Blinatumomab): What It Is and What to Expect

Blincyto is the brand name. Blinatumomab is the generic name. It is a small antibody with two grips. One grip holds CD19, a marker on B-cell leukemia cells. The other holds CD3 on a T cell. Pulling the two together forces the T cell to kill the leukemia cell. Nothing is engineered in a lab beforehand. The joining happens inside your body, for as long as the drug is running.

The label covers adults and children from one month of age.

• Leukemia in a first or second remission where sensitive testing still finds disease at 0.1% or more. This is called MRD-positive disease.
• Leukemia that has come back, or that never responded to earlier treatment.
• Leukemia without the Philadelphia chromosome, during the consolidation phase of a multi-step chemotherapy plan.

Most cycles are 28 days of nonstop infusion, then 14 days off. That makes a 42-day cycle. Some later cycles have a longer break. A small pump carries the bag, and you go about daily life attached to it. Nurses change the bag on a set schedule. The line and tubing need care at home, and your team will teach you.

Mistakes in preparing or hanging the bag are listed as a named risk in the label, so only trained staff handle it. A steroid is given before the first dose of a cycle to soften the reaction.

Two risks sit in the boxed warning.

Cytokine release syndrome. Fever, chills, low blood pressure and breathlessness caused by a surge of immune signals. It can be life-threatening or fatal.

Neurological toxicity, including a pattern called ICANS. Confusion, tremor, trouble speaking or writing, unsteadiness, or seizures. This too can be fatal.

Both are handled by pausing or stopping the infusion and giving steroids. Neither is something to ride out at home.

For MRD-positive disease, the label recommends hospital for the first 3 days of cycle one and the first 2 days of cycle two. For leukemia that has relapsed or not responded, it recommends the first 9 days of cycle one and the first 2 days of cycle two. Those are the windows when reactions are most likely.

The label advises against driving and against operating machinery during treatment, because confusion or a seizure can arrive without warning. Arrange lifts to appointments before you need them.

Other things the team watches: infection, tumor lysis syndrome as leukemia cells break down fast, low neutrophils with fever, rising liver enzymes, and pancreatitis, which can cause severe stomach pain that does not go away.

• Call 911 or go to an emergency department if you have a fit, collapse, cannot be woken properly, or your breathing becomes laboured. Say that you are on a continuous blinatumomab infusion, and bring the pump with you. Do not drive yourself.
• Ring the urgent number your team gave you the moment your temperature hits 100.4°F (38°C) or higher, you get shaking chills, or you feel faint when you stand. Those are the opening signs of cytokine release syndrome, and fever on this treatment is handled as an emergency, not something to ride out at home (CDC). Use that number at any hour; if nobody answers quickly, head to an emergency department and tell them you are on blinatumomab.
• Call your care team right away, at any hour, if you have new confusion, shaking hands, slurred words, handwriting that has gone wrong, or unsteadiness on your feet. These are signs of the nerve-related reaction, and MedlinePlus says to tell your doctor immediately (MedlinePlus).
• Call your care team right away, at any hour, if you get severe stomach pain that does not go away or spreads to your back, or if you pass much less urine than usual. The first can mean pancreatitis; the second can follow leukemia cells breaking down fast. MedlinePlus lists ongoing stomach pain that may spread to the back as a reason to call your doctor immediately (MedlinePlus).

Contact the team at once, at any hour, if the pump alarms, the line leaks, or the bag runs dry. Do not try to fix the infusion yourself.

• DailyMed: Blincyto label
• NCI: Blinatumomab
• CDC: Fever during cancer treatment